CA2395544A1 - Method of achieving persistent transgene expression - Google Patents

Method of achieving persistent transgene expression Download PDF

Info

Publication number
CA2395544A1
CA2395544A1 CA002395544A CA2395544A CA2395544A1 CA 2395544 A1 CA2395544 A1 CA 2395544A1 CA 002395544 A CA002395544 A CA 002395544A CA 2395544 A CA2395544 A CA 2395544A CA 2395544 A1 CA2395544 A1 CA 2395544A1
Authority
CA
Canada
Prior art keywords
composition according
nucleic acid
inflammatory
expression
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395544A
Other languages
English (en)
French (fr)
Inventor
Patrick Lu
David Leonard Ennist
Mervat Mina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395544A1 publication Critical patent/CA2395544A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002395544A 1999-12-28 2000-12-27 Method of achieving persistent transgene expression Abandoned CA2395544A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47301899A 1999-12-28 1999-12-28
US09/473,018 1999-12-28
PCT/EP2000/013297 WO2001048231A2 (en) 1999-12-28 2000-12-27 Method of achieving persistent transgene expression

Publications (1)

Publication Number Publication Date
CA2395544A1 true CA2395544A1 (en) 2001-07-05

Family

ID=23877847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395544A Abandoned CA2395544A1 (en) 1999-12-28 2000-12-27 Method of achieving persistent transgene expression

Country Status (8)

Country Link
EP (1) EP1242608A2 (de)
JP (1) JP2003522133A (de)
CN (2) CN1310679C (de)
AU (1) AU3164801A (de)
CA (1) CA2395544A1 (de)
IL (1) IL150485A0 (de)
NZ (1) NZ531527A (de)
WO (1) WO2001048231A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
CN101495498B (zh) * 2005-02-07 2013-09-18 基因信息公司 轻度骨关节炎生物标志物及其用途
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465529B1 (de) * 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
EP0804076A4 (de) * 1994-10-19 1998-10-21 Genetic Therapy Inc Gentherapy durch gleichzeitige und wiederholte verabreichung von adenovirus und immunsuppresiven mitteln
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
MY134778A (en) * 1995-10-23 2007-12-31 Hyal Pharmaceutical Australia Ltd Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE321882T1 (de) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre

Also Published As

Publication number Publication date
CN101011584A (zh) 2007-08-08
CN1310679C (zh) 2007-04-18
EP1242608A2 (de) 2002-09-25
NZ531527A (en) 2005-10-28
CN1433477A (zh) 2003-07-30
AU3164801A (en) 2001-07-09
WO2001048231A2 (en) 2001-07-05
IL150485A0 (en) 2002-12-01
JP2003522133A (ja) 2003-07-22
WO2001048231A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
Brigham et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy
US6080728A (en) Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
Gautam et al. Delivery systems for pulmonary gene therapy
US20210379203A1 (en) New Tools for Improving Gene Therapy and Use Thereof
CA2395544A1 (en) Method of achieving persistent transgene expression
AU732447B2 (en) Gene delivery and expression in areas inaccessible to direct protein delivery
Colledge Cystic fibrosis gene therapy
WO1996014837A1 (en) Gene therapy for hypercholesterolemia
US20090069257A1 (en) Method of achieving persistent Transgene expression
EP1898945B1 (de) Atemwegs-administration eines standort-deaktivierten fviia bei entzündungskrankheiten, die den atemtrakt betreffen
AU2004240187A1 (en) Method of achieving persistent transgene expression
US7074399B2 (en) Treatment of inflammation with p20
Rochat et al. Gene therapy for cystic fibrosis by means of aerosol
WO1996030051A1 (en) Use of surfactants for introducing genetic material into lung cells
EP1183361B1 (de) Gentherapy von lungenkrankheiten
US20060246074A1 (en) Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1- antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds
Bigger et al. Perspectives on gene therapy for cystic fibrosis airway disease
FLOTTE SECTION I GENETIC AND DEVELOPMENTAL BIOLOGY OF THE RESPIRATORY SYSTEM
Brigham et al. Rationale for the use of Gene Therapy for Critical Illness
Carter The Respiratory System as a Platform for Gene Delivery
CARTER 12 The Respiratory System as a Platform for Gene Delivery
Caplen et al. Gene Therapy for Respiratory Disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued